Your browser is no longer supported. Please, upgrade your browser.
Forma Therapeutics Holdings, Inc.
Index- P/E- EPS (ttm)-3.03 Insider Own0.50% Shs Outstand47.34M Perf Week2.56%
Market Cap1.17B Forward P/E- EPS next Y-3.98 Insider Trans0.00% Shs Float43.72M Perf Month6.38%
Income-135.80M PEG- EPS next Q-0.96 Inst Own91.60% Short Float7.04% Perf Quarter-5.29%
Sales- P/S- EPS this Y-120.20% Inst Trans0.09% Short Ratio10.58 Perf Half Y-25.76%
Book/sh12.24 P/B1.96 EPS next Y-13.80% ROA-22.70% Target Price- Perf Year-46.41%
Cash/sh10.96 P/C2.19 EPS next 5Y- ROE-24.00% 52W Range21.04 - 56.33 Perf YTD-31.20%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.38% Beta-
Dividend %- Quick Ratio17.90 Sales past 5Y- Gross Margin- 52W Low14.12% ATR1.30
Employees139 Current Ratio17.90 Sales Q/Q- Oper. Margin- RSI (14)52.61 Volatility5.90% 5.56%
OptionableYes Debt/Eq0.00 EPS Q/Q-48.10% Profit Margin- Rel Volume0.83 Prev Close24.11
ShortableYes LT Debt/Eq0.00 EarningsAug 13 BMO Payout- Avg Volume291.13K Price24.01
Recom1.60 SMA202.82% SMA501.42% SMA200-21.46% Volume240,963 Change-0.41%
Aug-02-21Initiated Craig Hallum Buy $58
Mar-31-21Reiterated H.C. Wainwright Buy $53 → $55
Feb-17-21Initiated Oppenheimer Outperform $60
Sep-08-20Initiated H.C. Wainwright Buy $53
Jul-14-20Initiated SVB Leerink Outperform $54
Jul-14-20Initiated Jefferies Buy $54
Jul-14-20Initiated Credit Suisse Outperform $64
Aug-13-21 07:05AM  
Aug-06-21 07:05AM  
Jul-27-21 08:05PM  
Jun-17-21 05:10AM  
Jun-14-21 07:05AM  
Jun-11-21 02:13PM  
May-20-21 07:05AM  
May-17-21 07:05AM  
May-14-21 07:05AM  
May-06-21 07:05AM  
Mar-30-21 11:08AM  
Mar-23-21 04:05PM  
Mar-03-21 08:50AM  
Feb-17-21 07:05AM  
Jan-20-21 07:05AM  
Jan-11-21 07:05AM  
Jan-07-21 07:05AM  
Dec-19-20 03:11AM  
Dec-15-20 04:35PM  
Dec-10-20 10:53PM  
Dec-08-20 04:15PM  
Dec-07-20 04:30PM  
Nov-12-20 07:05AM  
Nov-10-20 07:05AM  
Nov-04-20 01:11PM  
Oct-26-20 07:05AM  
Sep-20-20 10:40AM  
Sep-15-20 07:05AM  
Sep-09-20 07:05AM  
Aug-13-20 07:05AM  
Jul-30-20 07:05AM  
Jul-02-20 07:30PM  
Jun-23-20 04:05PM  
Jun-18-20 09:04PM  
Forma Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on development and commercialization of novel therapeutics for treatment of rare hematologic diseases and cancers. Its core product candidates for development include FT-4202, which is Phase 1 trial for the treatment of sickle cell disease and other hemoglobinopathies; and FT-7051 for the treatment of metastatic castration-resistant prostate cancer. The company is also developing Olutasidenib, a selective inhibitor for cancers with isocitrate dehydrogenase 1 gene mutations, which is in Phase II trial for the treatment of relapsed / refractory acute myeloid leukemia and Phase I trial to treat glioma; and FT-8225, a liver-targeted fatty-acid synthase inhibitor designed to block de novo lipogenesis in the liver. The company was founded in 2007 and is headquartered in Watertown, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Potts JeannetteSee RemarksDec 30Option Exercise5.053,40017,1703,400Jan 08 04:03 PM